{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:26:25Z","timestamp":1791926785805,"version":"4.3.4"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41574-026-01259-4","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:36:43Z","timestamp":1779446203000},"page":"543-553","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Aldosterone synthase inhibitors for the treatment of cardiovascular disease"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7963-0931","authenticated-orcid":false,"given":"Gian Paolo","family":"Rossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7533-4577","authenticated-orcid":false,"given":"Federico Bernardo","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4820-4876","authenticated-orcid":false,"given":"Andrea","family":"Cignarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3639-4086","authenticated-orcid":false,"given":"Teresa Maria","family":"Seccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"1259_CR1","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1093\/eurheartj\/ehr266","volume":"33","author":"J-C Reil","year":"2012","unstructured":"Reil, J.-C. et al. Aldosterone promotes atrial fibrillation. Eur. Heart J. 33, 2098\u20132108 (2012).","journal-title":"Eur. Heart J."},{"key":"1259_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/biom13061004","volume":"13","author":"M Crompton","year":"2023","unstructured":"Crompton, M., Skinner, L. J., Satchell, S. C. & Butler, M. J. Aldosterone: essential for life but damaging to the vascular endothelium. Biomolecules 13, 1004 (2023).","journal-title":"Biomolecules"},{"key":"1259_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"Monticone, S. et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 6, 41\u201350 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1259_CR4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ando.2020.02.006","volume":"82","author":"GP Rossi","year":"2021","unstructured":"Rossi, G. P., Seccia, T. M., Maiolino, G. & Cesari, M. The cardiovascular consequences of hyperaldosteronism. Ann. Endocrinol. 82, 174\u2013178 (2021).","journal-title":"Ann. Endocrinol."},{"key":"1259_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/01.mnh.0000165889.60254.98","volume":"14","author":"NJ Brown","year":"2005","unstructured":"Brown, N. J. Aldosterone and end-organ damage. Curr. Opin. Nephrol. Hypertens. 14, 235\u2013241 (2005).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"1259_CR6","doi-asserted-by":"publisher","first-page":"H670","DOI":"10.1152\/ajpheart.00419.2023","volume":"326","author":"S Verma","year":"2024","unstructured":"Verma, S. et al. Aldosterone and aldosterone synthase inhibitors in cardiorenal disease. Am. J. Physiol. Heart Circ. Physiol. 326, H670\u2013H688 (2024).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1259_CR7","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1161\/HYPERTENSIONAHA.115.07074","volume":"67","author":"M Briet","year":"2016","unstructured":"Briet, M. et al. Aldosterone-induced vascular remodeling and endothelial dysfunction require functional angiotensin type 1a receptors. Hypertension 67, 897\u2013905 (2016).","journal-title":"Hypertension"},{"key":"1259_CR8","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1210\/jc.2003-032149","volume":"89","author":"DG Levy","year":"2004","unstructured":"Levy, D. G., Rocha, R. & Funder, J. W. Distinguishing the antihypertensive and electrolyte effects of eplerenone. J. Clin. Endocrinol. Metab. 89, 2736\u20132740 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1259_CR9","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1161\/HYPERTENSIONAHA.124.22642","volume":"81","author":"GP Rossi","year":"2024","unstructured":"Rossi, G. P., Rossi, F. B., Guarnieri, C., Rossitto, G. & Seccia, T. M. Clinical management of primary aldosteronism: an update. Hypertension 81, 1845\u20131856 (2024).","journal-title":"Hypertension"},{"key":"1259_CR10","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1210\/jc.2008-0251","volume":"93","author":"GP Rossi","year":"2008","unstructured":"Rossi, G. P. et al. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J. Clin. Endocrinol. Metab. 93, 2566\u20132571 (2008).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1259_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jsbmb.2003.09.010","volume":"87","author":"LK Malendowicz","year":"2003","unstructured":"Malendowicz, L. K. et al. Effects of leptin and leptin fragments on steroid secretion of freshly dispersed rat adrenocortical cells. J. Steroid Biochem. Mol. Biol. 87, 265\u2013268 (2003).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"1259_CR12","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1161\/CIRCULATIONAHA.115.018226","volume":"132","author":"AC Huby","year":"2015","unstructured":"Huby, A. C. et al. Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation 132, 2134\u20132145 (2015).","journal-title":"Circulation"},{"key":"1259_CR13","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"Milliez, P. et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 45, 1243\u20131248 (2005).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1259_CR14","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/HJH.0000000000002250","volume":"38","author":"TM Seccia","year":"2020","unstructured":"Seccia, T. M. et al. Atrial fibrillation as presenting sign of primary aldosteronism: results of the prospective appraisal on the prevalence of primary aldosteronism in hypertensive (PAPPHY) study. J. Hypertens. 38, 332\u2013339 (2020).","journal-title":"J. Hypertens."},{"key":"1259_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijcard.2016.01.007","volume":"206","author":"TM Seccia","year":"2016","unstructured":"Seccia, T. M., Caroccia, B., Muiesan, M. L. & Rossi, G. P. Atrial fibrillation and arterial hypertension: a common duet with dangerous consequences where the renin angiotensin-aldosterone system plays an important role. Int. J. Cardiol. 206, 71\u201376 (2016).","journal-title":"Int. J. Cardiol."},{"key":"1259_CR16","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1161\/HYPERTENSIONAHA.112.197111","volume":"60","author":"M Reincke","year":"2012","unstructured":"Reincke, M. et al. Observational study mortality in treated primary aldosteronism: the German Conn\u2019s registry. Hypertension 60, 618\u2013624 (2012).","journal-title":"Hypertension"},{"key":"1259_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/srep32103","volume":"6","author":"VC Wu","year":"2016","unstructured":"Wu, V. C. et al. Long term outcome of Aldosteronism after target treatments. Sci. Rep. 6, 32103 (2016).","journal-title":"Sci. Rep."},{"key":"1259_CR18","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/S0140-6736(08)60834-X","volume":"371","author":"S Douma","year":"2008","unstructured":"Douma, S. et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 371, 1921\u20131926 (2008).","journal-title":"Lancet"},{"key":"1259_CR19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S0140-6736(14)61468-9","volume":"386","author":"NR Poulter","year":"2015","unstructured":"Poulter, N. R., Prabhakaran, D. & Caulfield, M. Hypertension. Lancet 386, 801\u2013812 (2015).","journal-title":"Lancet"},{"key":"1259_CR20","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy, J. W. et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur. Heart J. 45, 3912\u20134018 (2024).","journal-title":"Eur. Heart J."},{"key":"1259_CR21","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams, B. et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386, 2059\u20132068 (2015).","journal-title":"Lancet"},{"key":"1259_CR22","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"MK Nishizaka","year":"2003","unstructured":"Nishizaka, M. K., Zaman, M. A. & Calhoun, D. A. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am. J. Hypertens. 16, 925\u2013930 (2003).","journal-title":"Am. J. Hypertens."},{"key":"1259_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1524-6175.2007.06334.x","volume":"9","author":"DA Calhoun","year":"2007","unstructured":"Calhoun, D. A. Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J. Clin. Hypertens. 9, 19\u201324 (2007).","journal-title":"J. Clin. Hypertens."},{"key":"1259_CR24","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","volume":"49","author":"N Chapman","year":"2007","unstructured":"Chapman, N. et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49, 839\u2013845 (2007).","journal-title":"Hypertension"},{"key":"1259_CR25","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1042\/CS20200340","volume":"134","author":"F Torresan","year":"2020","unstructured":"Torresan, F. et al. Resolution of drug-resistant hypertension by adrenal vein sampling-guided adrenalectomy: a proof-of-concept study. Clin. Sci. 134, 1265\u20131278 (2020).","journal-title":"Clin. Sci."},{"key":"1259_CR26","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1210\/endrev\/bnaf007","volume":"46","author":"GP Rossi","year":"2025","unstructured":"Rossi, G. P., Battistel, M., Seccia, T. M., Rossi, F. B. & Rossitto, G. Subtyping of primary aldosteronism by adrenal venous sampling. Endocr. Rev. 46, 501\u2013517 (2025).","journal-title":"Endocr. Rev."},{"key":"1259_CR27","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.025952","volume":"11","author":"AF Turcu","year":"2022","unstructured":"Turcu, A. F. et al. Primary aldosteronism screening rates differ with sex, race, and comorbidities. J. Am. Heart Assoc. 11, e025952 (2022).","journal-title":"J. Am. Heart Assoc."},{"key":"1259_CR28","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi, G. P. et al. A Prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J. Am. Coll. Cardiol. 48, 2293\u20132300 (2006).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1259_CR29","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2174\/1389450033490948","volume":"4","author":"KT Weber","year":"2003","unstructured":"Weber, K. T. et al. Aldosteronism in heart failure: a proinflammatory\/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. Curr. Drug. Targets 4, 505\u2013516 (2003).","journal-title":"Curr. Drug. Targets"},{"key":"1259_CR30","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1056\/NEJM197203022860901","volume":"286","author":"HR Brunner","year":"1972","unstructured":"Brunner, H. R. et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N. Engl. J. Med. 286, 441\u2013449 (1972).","journal-title":"N. Engl. J. Med."},{"key":"1259_CR31","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1056\/NEJM199402173300716","volume":"330","author":"MH Alderman","year":"1994","unstructured":"Alderman, M. H., Sealey, J. E. & Laragh, J. H. Plasma renin activity and ischemic heart disease. N. Engl. J. Med. 330, 506\u2013507 (1994).","journal-title":"N. Engl. J. Med."},{"key":"1259_CR32","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1161\/01.HYP.27.5.1039","volume":"27","author":"GP Rossi","year":"1996","unstructured":"Rossi, G. P. et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 27, 1039\u20131045 (1996).","journal-title":"Hypertension"},{"key":"1259_CR33","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1161\/01.CIR.95.6.1471","volume":"95","author":"GP Rossi","year":"1997","unstructured":"Rossi, G. P. et al. Remodeling of the left ventricle in primary aldosteronism due to Conn\u2019s adenoma. Circulation 95, 1471\u20131478 (1997).","journal-title":"Circulation"},{"key":"1259_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1161\/01.HYP.0000023182.68420.EB","volume":"40","author":"GP Rossi","year":"2002","unstructured":"Rossi, G. P. et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 40, 23\u201327 (2002).","journal-title":"Hypertension"},{"key":"1259_CR35","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1161\/CIRCIMAGING.112.974576","volume":"5","author":"EM Freel","year":"2012","unstructured":"Freel, E. M. et al. Demonstration of blood pressure-independent noninfarct myocardial fibrosis in primary aldosteronism: a cardiac magnetic resonance imaging study. Circ. Cardiovasc. Imaging 5, 740\u2013747 (2012).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"1259_CR36","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1097\/00004872-199512010-00054","volume":"13","author":"J-M Halimi","year":"1995","unstructured":"Halimi, J.-M. & Mimran, A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J. Hypertens. 13, 1801\u20131802 (1995).","journal-title":"J. Hypertens."},{"key":"1259_CR37","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi, G. P. et al. Renal damage in primary aldosteronism: results of the PAPY study. Hypertension 48, 232\u2013238 (2006).","journal-title":"Hypertension"},{"key":"1259_CR38","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1161\/HYPERTENSIONAHA.124.23700","volume":"81","author":"F Torresan","year":"2024","unstructured":"Torresan, F. et al. Water and electrolyte content in hypertension in the skin (WHYSKI) in primary aldosteronism. Hypertension 81, 2468\u20132478 (2024).","journal-title":"Hypertension"},{"key":"1259_CR39","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1161\/HYPERTENSIONAHA.116.08956","volume":"69","author":"TM Seccia","year":"2017","unstructured":"Seccia, T. M. et al. Arterial hypertension, atrial fibrillation, and hyperaldosteronism. Hypertension 69, 545\u2013550 (2017).","journal-title":"Hypertension"},{"key":"1259_CR40","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.113.01316","volume":"62","author":"G Rossi","year":"2013","unstructured":"Rossi, G. et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism heart. Hypertension 62, 62\u201369 (2013).","journal-title":"Hypertension"},{"key":"1259_CR41","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1161\/HYPERTENSIONAHA.117.10596","volume":"71","author":"GP Rossi","year":"2018","unstructured":"Rossi, G. P. et al. Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term. Hypertension 71, 585\u2013591 (2018).","journal-title":"Hypertension"},{"key":"1259_CR42","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1161\/01.RES.67.6.1355","volume":"67","author":"CG Brilla","year":"1990","unstructured":"Brilla, C. G., Pick, R., Tan, L. B., Janicki, J. S. & Weber, K. T. Remodeling of the rat right and left ventricles in experimental hypertension. Circ. Res. 67, 1355\u20131364 (1990).","journal-title":"Circ. Res."},{"key":"1259_CR43","first-page":"107","volume":"88","author":"KT Weber","year":"1993","unstructured":"Weber, K. T. et al. Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Res. Cardiol. 88, 107\u2013124 (1993).","journal-title":"Basic Res. Cardiol."},{"key":"1259_CR44","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3109\/08037059209077497","volume":"1","author":"KT Weber","year":"1992","unstructured":"Weber, K. T. et al. Pathologic hypertrophy with fibrosis: the structural basis for myocardial failure. Blood Press. 1, 75\u201385 (1992).","journal-title":"Blood Press."},{"key":"1259_CR45","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709\u2013717 (1999).","journal-title":"N. Engl. J. Med."},{"key":"1259_CR46","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt, B. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309\u20131321 (2003).","journal-title":"N. Engl. J. Med."},{"key":"1259_CR47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad, F. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11\u201321 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1259_CR48","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt, B. et al. Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 370, 1383\u20131392 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1259_CR49","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1056\/NEJMc1612601","volume":"376","author":"S de Denus","year":"2017","unstructured":"de Denus, S. et al. Spironolactone metabolites in TOPCAT \u2014 new insights into regional variation. N. Engl. J. Med. 376, 1690\u20131692 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1259_CR50","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1161\/HYPERTENSIONAHA.107.109314","volume":"52","author":"B Pitt","year":"2008","unstructured":"Pitt, B. et al. History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. Hypertension 52, 271\u2013278 (2008).","journal-title":"Hypertension"},{"key":"1259_CR51","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt, B. et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N. Engl. J. Med. 385, 2252\u20132263 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1259_CR52","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","volume":"145","author":"G Filippatos","year":"2022","unstructured":"Filippatos, G. et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation 145, 437\u2013447 (2022).","journal-title":"Circulation"},{"key":"1259_CR53","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219\u20132229 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1259_CR54","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon, S. D. et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 391, 1475\u20131485 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1259_CR55","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","volume":"30","author":"M Vaduganathan","year":"2024","unstructured":"Vaduganathan, M. et al. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat. Med. 30, 3758\u20133764 (2024).","journal-title":"Nat. Med."},{"key":"1259_CR56","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh, T. A. et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599\u20133726 (2021).","journal-title":"Eur. Heart J."},{"key":"1259_CR57","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jacc.2005.08.022","volume":"46","author":"SA Hunt","year":"2005","unstructured":"Hunt, S. A. ACC\/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. Cardiol. 46, e1\u2013e82 (2005).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1259_CR58","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/ejhf.74","volume":"16","author":"RJJ Mentz","year":"2014","unstructured":"Mentz, R. J. J. et al. Decongestion in acute heart failure. Eur. J. Heart Fail. 16, 471\u2013482 (2014).","journal-title":"Eur. J. Heart Fail."},{"key":"1259_CR59","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"D Juurlink","year":"2004","unstructured":"Juurlink, D. et al. Rates of hyperkalemia after publication of the randomized Aldactone evaluation study. N. Engl. J. Med. 351, 543\u2013551 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1259_CR60","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0002-9343(01)00642-8","volume":"110","author":"H Schepkens","year":"2001","unstructured":"Schepkens, H., Vanholder, R., Billiouw, J.-M. & Lameire, N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am. J. Med. 110, 438\u2013441 (2001).","journal-title":"Am. J. Med."},{"key":"1259_CR61","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia, G. et al. 2023 ESH guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the European Renal Association (ERA) and the International Society of Hypertension. J. Hypertens. 41, 1874\u20132071 (2023).","journal-title":"J. Hypertens."},{"key":"1259_CR62","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1161\/HYPERTENSIONAHA.118.12191","volume":"73","author":"RM Carey","year":"2019","unstructured":"Carey, R. M., Sakhuja, S., Calhoun, D. A., Whelton, P. K. & Muntner, P. Prevalence of apparent treatment-resistant hypertension in the United States: comparison of the 2008 and 2018 American Heart Association scientific statements on resistant hypertension. Hypertension 73, 424\u2013431 (2019).","journal-title":"Hypertension"},{"key":"1259_CR63","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/clc.20324","volume":"31","author":"A Struthers","year":"2008","unstructured":"Struthers, A., Krum, H. & Williams, G. H. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin. Cardiol. 31, 153\u2013158 (2008).","journal-title":"Clin. Cardiol."},{"key":"1259_CR64","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s11906-022-01177-6","volume":"24","author":"Y Tezuka","year":"2022","unstructured":"Tezuka, Y. & Ito, S. The time to reconsider mineralocorticoid receptor blocking strategy: arrival of nonsteroidal mineralocorticoid receptor blockers. Curr. Hypertens. Rep. 24, 215\u2013224 (2022).","journal-title":"Curr. Hypertens. Rep."},{"key":"1259_CR65","first-page":"E719","volume":"260","author":"M Wehling","year":"1991","unstructured":"Wehling, M., K\u00e4smayr, J. & Theisen, K. Rapid effects of mineralocorticoids on sodium-proton exchanger: genomic or nongenomic pathway? Am. J. Physiol. 260, E719\u2013E726 (1991).","journal-title":"Am. J. Physiol."},{"key":"1259_CR66","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1161\/01.RES.76.6.973","volume":"76","author":"M Wehling","year":"1995","unstructured":"Wehling, M., Neylon, C. B., Fullerton, M., Bobik, A. & Funder, J. W. Nongenomic effects of aldosterone on intracellular Ca2+ in vascular smooth muscle cells. Circ. Res. 76, 973\u2013979 (1995).","journal-title":"Circ. Res."},{"key":"1259_CR67","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/1440-1681.12157","volume":"40","author":"RD Feldman","year":"2013","unstructured":"Feldman, R. D. & Gros, R. Vascular effects of aldosterone: sorting out the receptors and the ligands. Clin. Exp. Pharmacol. Physiol. 40, 916\u2013921 (2013).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"1259_CR68","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.steroids.2007.12.010","volume":"73","author":"BMW Schmidt","year":"2008","unstructured":"Schmidt, B. M. W. Rapid non-genomic effects of aldosterone on the renal vasculature. Steroids 73, 961\u2013965 (2008).","journal-title":"Steroids"},{"key":"1259_CR69","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.pharmthera.2005.10.010","volume":"111","author":"O Sk\u00f8tt","year":"2006","unstructured":"Sk\u00f8tt, O. et al. Rapid actions of aldosterone in vascular health and disease-friend or foe? Pharmacol. Ther. 111, 495\u2013507 (2006).","journal-title":"Pharmacol. Ther."},{"key":"1259_CR70","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0021-9150(02)00363-5","volume":"166","author":"P Romagni","year":"2003","unstructured":"Romagni, P., Rossi, F., Guerrini, L., Quirini, C. & Santiemma, V. Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 166, 345\u2013349 (2003).","journal-title":"Atherosclerosis"},{"key":"1259_CR71","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-physiol-042022-015223","volume":"86","author":"J Ibarrola","year":"2025","unstructured":"Ibarrola, J. & Jaffe, I. Z. The mineralocorticoid receptor in the vasculature: friend or foe? Annu. Rev. Physiol. 86, 49\u201370 (2025).","journal-title":"Annu. Rev. Physiol."},{"key":"1259_CR72","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/cvr\/cvn064","volume":"79","author":"M Yamada","year":"2008","unstructured":"Yamada, M., Kushibiki, M., Osanai, T., Tomita, H. & Okumura, K. Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization. Cardiovasc. Res. 79, 169\u2013178 (2008).","journal-title":"Cardiovasc. Res."},{"key":"1259_CR73","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/cvr\/cvs016","volume":"94","author":"WW Batenburg","year":"2012","unstructured":"Batenburg, W. W., Jansen, P. M., van den Bogaerdt, A. J. & Danser A. H. J. Angiotensin II-aldosterone interaction in human coronary microarteries involves GPR30, EGFR, and endothelial NO synthase. Cardiovasc. Res. 94, 136\u2013143 (2012).","journal-title":"Cardiovasc. Res."},{"key":"1259_CR74","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1210\/mend.14.10.0532","volume":"14","author":"EJ Filardo","year":"2000","unstructured":"Filardo, E. J., Quinn, J. A., Bland, K. I. & Frackelton, A. R. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 14, 1649\u20131660 (2000).","journal-title":"Mol. Endocrinol."},{"key":"1259_CR75","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1210\/en.2008-1664","volume":"150","author":"SH Lindsey","year":"2009","unstructured":"Lindsey, S. H., Cohen, J. A., Brosnihan, K. B., Gallagher, P. E. & Chappell, M. C. Chronic treatment with the G protein-coupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2.Lewis rats. Endocrinology 150, 3753\u20133758 (2009).","journal-title":"Endocrinology"},{"key":"1259_CR76","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1093\/cvr\/cvaa075","volume":"117","author":"QN Dinh","year":"2021","unstructured":"Dinh, Q. N. et al. Aldosterone-induced hypertension is sex-dependent, mediated by T cells and sensitive to GPER activation. Cardiovasc. Res. 117, 960\u2013970 (2021).","journal-title":"Cardiovasc. Res."},{"key":"1259_CR77","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41574-023-00822-7","volume":"19","author":"ER Prossnitz","year":"2023","unstructured":"Prossnitz, E. R. & Barton, M. The G protein-coupled oestrogen receptor GPER in health and disease: an update. Nat. Rev. Endocrinol. 19, 407\u2013424 (2023).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1259_CR78","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1124\/molpharm.121.000259","volume":"100","author":"J Tutzauer","year":"2021","unstructured":"Tutzauer, J. et al. Ligand-independent G protein-coupled estrogen receptor\/G protein-coupled receptor 30 activity: lack of receptor-dependent effects of G-1 and 17\u03b2-estradiol. Mol. Pharmacol. 100, 271\u2013282 (2021).","journal-title":"Mol. Pharmacol."},{"key":"1259_CR79","doi-asserted-by":"publisher","first-page":"6316","DOI":"10.1210\/jc.2019-00043","volume":"104","author":"B Caroccia","year":"2019","unstructured":"Caroccia, B. et al. Aldosterone stimulates its biosynthesis via a novel GPER-mediated mechanism. J. Clin. Endocrinol. Metab. 104, 6316\u20136324 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1259_CR80","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/clpt.1980.75","volume":"27","author":"LE Ramsay","year":"1980","unstructured":"Ramsay, L. E., Hettiarachchi, J., Fraser, R. & Morton, J. J. Amiloride, spironolactone, and potassium chloride in thiazide-treated hypertensive patients. Clin. Pharmacol. Ther. 27, 533\u2013543 (1980).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1259_CR81","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2008.10.029","volume":"301","author":"JW Funder","year":"2009","unstructured":"Funder, J. W. & Mihailidou, A. S. Aldosterone and mineralocorticoid receptors: clinical studies and basic biology. Mol. Cell. Endocrinol. 301, 2\u20136 (2009).","journal-title":"Mol. Cell. Endocrinol."},{"key":"1259_CR82","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.252004","volume":"318","author":"C Kopp","year":"2026","unstructured":"Kopp, C. et al. 7-T Potassium (39K) MRI to assess muscle K+ depletion in primary aldosteronism. Radiology 318, e252004 (2026).","journal-title":"Radiology"},{"key":"1259_CR83","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/nm.1879","volume":"14","author":"S Shibata","year":"2008","unstructured":"Shibata, S. et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat. Med. 14, 1370\u20131376 (2008).","journal-title":"Nat. Med."},{"key":"1259_CR84","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1161\/HYPERTENSIONAHA.121.17263","volume":"78","author":"D Hirohama","year":"2021","unstructured":"Hirohama, D. et al. Activation of Rac1-mineralocorticoid receptor pathway contributes to renal injury in salt-loaded db\/db mice. Hypertension 78, 82\u201393 (2021).","journal-title":"Hypertension"},{"key":"1259_CR85","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/nrneph.2012.282","volume":"9","author":"M Nagase","year":"2013","unstructured":"Nagase, M. & Fujita, T. Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nat. Rev. Nephrol. 9, 86\u201398 (2013).","journal-title":"Nat. Rev. Nephrol."},{"key":"1259_CR86","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10741-005-2344-2","volume":"10","author":"JW Funder","year":"2005","unstructured":"Funder, J. W. Mineralocorticoid receptors: distribution and activation. Heart Fail. Rev. 10, 15\u201322 (2005).","journal-title":"Heart Fail. Rev."},{"key":"1259_CR87","doi-asserted-by":"publisher","DOI":"10.1530\/EC-23-0121","volume":"12","author":"K Hung","year":"2023","unstructured":"Hung, K. et al. Influence of autonomous cortisol secretion in patients with primary aldosteronism: subtype analysis and postoperative outcome. Endocr. Connect. 12, e230121 (2023).","journal-title":"Endocr. Connect."},{"key":"1259_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105332","volume":"163","author":"L Lenzini","year":"2021","unstructured":"Lenzini, L., Zanotti, G., Bonchio, M. & Rossi, G. P. Aldosterone synthase inhibitors for cardiovascular diseases: a comprehensive review of preclinical, clinical and in silico data. Pharmacol. Res. 163, 105332 (2021).","journal-title":"Pharmacol. Res."},{"key":"1259_CR89","doi-asserted-by":"publisher","first-page":"5179","DOI":"10.1021\/jm500140c","volume":"57","author":"L Yin","year":"2014","unstructured":"Yin, L. et al. Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors. J. Med. Chem. 57, 5179\u20135189 (2014).","journal-title":"J. Med. Chem."},{"key":"1259_CR90","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1073\/pnas.89.4.1458","volume":"89","author":"T Kawamoto","year":"1992","unstructured":"Kawamoto, T. et al. Role of steroid 11,6-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans. Proc. Natl. Acad. Sci. USA 89, 1458\u20131462 (1992).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1259_CR91","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","volume":"56","author":"L Amar","year":"2010","unstructured":"Amar, L. et al. Aldosterone synthase inhibition with LCI699. Hypertension 56, 831\u2013838 (2010).","journal-title":"Hypertension"},{"key":"1259_CR92","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","volume":"8","author":"R Pivonello","year":"2020","unstructured":"Pivonello, R. et al. Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol. 8, 748\u2013761 (2020).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1259_CR93","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","volume":"388","author":"MW Freeman","year":"2022","unstructured":"Freeman, M. W. et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N. Eng. J. Med. 388, 395\u2013405 (2022).","journal-title":"N. Eng. J. Med."},{"key":"1259_CR94","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1001\/jama.2023.16029","volume":"330","author":"LJ Laffin","year":"2023","unstructured":"Laffin, L. J. et al. Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the Target-HTN randomized clinical trial. JAMA 330, 1140\u20131150 (2023).","journal-title":"JAMA"},{"key":"1259_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102576","volume":"71","author":"P Mulatero","year":"2024","unstructured":"Mulatero, P. et al. Safety and efficacy of once-daily dexfadrostat phosphate in patients with primary aldosteronism: a randomised, parallel group, multicentre, phase 2 trial. EClinicalMedicine 71, 102576 (2024).","journal-title":"EClinicalMedicine"},{"key":"1259_CR96","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1056\/NEJMc2508629","volume":"393","author":"AF Turcu","year":"2025","unstructured":"Turcu, A. F. et al. Phase 2a study of baxdrostat in primary aldosteronism. N. Engl. J. Med. 393, 515\u2013518 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1259_CR97","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","volume":"393","author":"JM Flack","year":"2025","unstructured":"Flack, J. M. et al. Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension. N. Engl. J. Med. 393, 1363\u20131374 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1259_CR98","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jama.2025.9413","volume":"334","author":"M Saxena","year":"2025","unstructured":"Saxena, M. et al. Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the Launch-HTN randomized clinical trial. JAMA 334, 409\u2013418 (2025).","journal-title":"JAMA"},{"key":"1259_CR99","doi-asserted-by":"publisher","first-page":"9083","DOI":"10.1007\/s00210-025-03838-0","volume":"398","author":"F Schulze","year":"2025","unstructured":"Schulze, F. et al. Phase 1 studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 690517 (vicadrostat), a novel aldosterone synthase inhibitor, in healthy male volunteers. Naunyn Schmiedebergs Arch. Pharmacol. 398, 9083\u20139098 (2025).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"1259_CR100","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","volume":"403","author":"KR Tuttle","year":"2024","unstructured":"Tuttle, K. R. et al. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. Lancet 403, 379\u2013390 (2024).","journal-title":"Lancet"},{"key":"1259_CR101","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1681\/ASN.0000000849","volume":"37","author":"JP Dwyer","year":"2026","unstructured":"Dwyer, J. P. et al. Efficacy and safety of baxdrostat in participants with CKD and uncontrolled hypertension. J. Am. Soc. Nephrol. 37, 299\u2013311 (2026).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1259_CR102","doi-asserted-by":"publisher","first-page":"108486","DOI":"10.1016\/j.steroids.2019.108486","volume":"152","author":"GP Rossi","year":"2019","unstructured":"Rossi, G. P., Caroccia, B. & Seccia, T. M. Role of estrogen receptors in modulating aldosterone biosynthesis and blood pressure. Steroids 152, 108486 (2019).","journal-title":"Steroids"},{"key":"1259_CR103","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1161\/HYPERTENSIONAHA.116.07660","volume":"68","author":"B Caroccia","year":"2016","unstructured":"Caroccia, B., Seccia, T. M., Barton, M. & Rossi, G. P. Estrogen signaling in the adrenal cortex. Hypertension 68, 840\u2013848 (2016).","journal-title":"Hypertension"},{"key":"1259_CR104","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.1210\/en.2014-1270","volume":"155","author":"K Barrett Mueller","year":"2014","unstructured":"Barrett Mueller, K. et al. Estrogen receptor inhibits mineralocorticoid receptor transcriptional regulatory function. Endocrinology 155, 4461\u20134472 (2014).","journal-title":"Endocrinology"},{"key":"1259_CR105","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1161\/HYPERTENSIONAHA.114.03127","volume":"63","author":"JW Funder","year":"2014","unstructured":"Funder, J. W. Sensitivity to aldosterone: plasma levels are not the full story. Hypertension 63, 1168\u20131170 (2014).","journal-title":"Hypertension"},{"key":"1259_CR106","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1161\/HYPERTENSIONAHA.113.02989","volume":"63","author":"W Tu","year":"2014","unstructured":"Tu, W. et al. Racial differences in sensitivity of blood pressure to aldosterone. Hypertension 63, 1212\u20131218 (2014).","journal-title":"Hypertension"},{"key":"1259_CR107","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1161\/01.HYP.0000154364.00763.d5","volume":"45","author":"CE Grim","year":"2005","unstructured":"Grim, C. E. et al. Hyperaldosteronism and hypertension: ethnic differences. Hypertension 45, 766\u2013772 (2005).","journal-title":"Hypertension"},{"key":"1259_CR108","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.eprac.2021.11.085","volume":"28","author":"K Zekarias","year":"2022","unstructured":"Zekarias, K. & Tessier, K. M. Screening rate for primary aldosteronism among patients with apparent treatment-resistant hypertension: retrospective analysis of current practice. Endocr. Pract. 28, 271\u2013275 (2022).","journal-title":"Endocr. Pract."},{"key":"1259_CR109","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1016\/j.jacc.2021.06.017","volume":"78","author":"MO Ogunniyi","year":"2021","unstructured":"Ogunniyi, M. O., Commodore-Mensah, Y. & Ferdinand, K. C. Race, ethnicity, hypertension, and heart disease: JACC Focus Seminar 1\/9. J. Am. Coll. Cardiol. 78, 2460\u20132470 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1259_CR110","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1093\/ajh\/hpt276","volume":"27","author":"DE Rifkin","year":"2014","unstructured":"Rifkin, D. E. et al. Association of renin and aldosterone with ethnicity and blood pressure: the multi-ethnic study of atherosclerosis. Am. J. Hypertens. 27, 801\u2013810 (2014).","journal-title":"Am. J. Hypertens."},{"key":"1259_CR111","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1161\/CIRCHEARTFAILURE.120.007264","volume":"13","author":"A Nayak","year":"2020","unstructured":"Nayak, A., Hicks, A. J. & Morris, A. A. Understanding the complexity of heart failure risk and treatment in black patients. Circ. Heart Fail. 13, 2460\u20132470 (2020).","journal-title":"Circ. Heart Fail."},{"key":"1259_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.102670","volume":"13","author":"DD Agoons","year":"2025","unstructured":"Agoons, D. D. et al. Aldosterone, subclinical cardiac dysfunction and heart failure subtypes: the Jackson Heart Study. JACC Heart Fail. 13, 102670 (2025).","journal-title":"JACC Heart Fail."},{"key":"1259_CR113","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1210\/clinem\/dgz017","volume":"105","author":"G Rossitto","year":"2020","unstructured":"Rossitto, G. et al. Subtyping of primary aldosteronism in the AVIS-2 study: assessment of selectivity and lateralization. J. Clin. Endocrinol. Metab. 105, 2042\u20132052 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1259_CR114","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1161\/HYPERTENSIONAHA.123.21247","volume":"80","author":"GP Rossi","year":"2023","unstructured":"Rossi, G. P. et al. Unilaterally selective adrenal vein sampling for identification of surgically curable primary aldosteronism. Hypertension 80, 2003\u20132013 (2023).","journal-title":"Hypertension"},{"key":"1259_CR115","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1161\/HYPERTENSIONAHA.119.13463","volume":"74","author":"GP Rossi","year":"2019","unstructured":"Rossi, G. P. et al. The clinical outcomes of 1625 patients with primary aldosteronism subtyped with adrenal vein sampling. Hypertension 74, 800\u2013808 (2019).","journal-title":"Hypertension"},{"key":"1259_CR116","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1001\/jamacardio.2018.2003","volume":"3","author":"GL Hundemer","year":"2018","unstructured":"Hundemer, G. L., Curhan, G. C., Yozamp, N., Wang, M. & Vaidya, A. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMA Cardiol. 3, 768\u2013774 (2018).","journal-title":"JAMA Cardiol."},{"key":"1259_CR117","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","volume":"72","author":"GL Hundemer","year":"2018","unstructured":"Hundemer, G. L., Curhan, G. C., Yozamp, N., Wang, M. & Vaidya, A. Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension 72, 658\u2013666 (2018).","journal-title":"Hypertension"}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01259-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01259-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01259-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:01:42Z","timestamp":1786449702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01259-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":117,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1259"],"URL":"https:\/\/doi.org\/10.1038\/s41574-026-01259-4","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"30 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.P.R. has given paid seminars sponsored by AstraZeneca. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}